Cancer

Decades after a small breast cancer vaccine trial, researchers link lasting immune memory to CD27

January 30, 2026 Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

More than 20 years after a small Duke-led clinical trial tested an experimental breast cancer vaccine, Duke Health says all participating women are still alive—an outcome researchers describe as unusual for metastatic disease. Follow-up analyses found long-lived immune cells marked by CD27, and mouse experiments suggest that stimulating CD27 can boost vaccine-driven tumor control.

Early immunotherapy timing boosts lung cancer survival

A randomized trial shows that administering cancer immunotherapy before 3pm can nearly double survival time for patients with non-small cell lung cancer. Researchers found significant benefits from aligning treatment with circadian rhythms during the initial cycles. This marks the strongest evidence yet for chronotherapy in oncology.

Scientists identify periostin's role in pancreatic cancer spread

January 30, 2026 Ti AI ṣe iroyin

Researchers in Brazil have uncovered how pancreatic cancer uses a protein called periostin to invade nerves and spread early. This discovery explains the disease's aggressiveness and suggests new treatment targets. The findings, published in Molecular and Cellular Endocrinology, highlight the tumor's ability to remodel surrounding tissue.

Ìlera

Statins block cancer's PD-L1 evasion in immunotherapy

America

Hatuey Project donates supplies for pediatric cancer care in Cuba

Ìlera

Moffitt researchers introduce ALFA-K to map fitness “landscapes” of chromosome changes in cancer evolution

Chemotherapy alters gut bacteria to block cancer metastasis

A new study reveals that chemotherapy's damage to the gut lining unexpectedly rewires the microbiota, producing a compound that strengthens immune defenses against cancer spread. This process reduces immunosuppressive cells and enhances resistance to metastasis, particularly in the liver. Patient data links higher levels of this compound to improved survival in colorectal cancer cases.

Ibuprofen linked to lower endometrial cancer risk

January 20, 2026 Ti AI ṣe iroyin

New research indicates that regular use of ibuprofen, a common painkiller, may reduce the risk of endometrial cancer by up to 25% in certain women. This finding comes from a large-scale study analyzing over 42,000 participants, highlighting the drug's anti-inflammatory properties. However, experts caution against using it for prevention due to potential side effects.

Northwestern antibody targets pancreatic cancer's immune evasion

Scientists at Northwestern Medicine have developed an antibody that counters pancreatic cancer's sugar-based disguise, enabling the immune system to attack tumors more effectively. In mouse studies, the therapy slowed tumor growth by restoring immune activity. The team is preparing the antibody for human trials.

Japan releases first national five-year cancer survival rates

January 15, 2026 Ti AI ṣe iroyin

Japan's health ministry has released the first five-year survival rates for cancer patients nationwide, based on data from nearly 990,000 diagnoses in 2016. Prostate cancer recorded the highest rate at 92.1%, while pancreatic cancer had the lowest at 11.8%. These figures, drawn from the national cancer registry, underscore variations across cancer types.

January 30, 2026 01:07